|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Andre N and Schmiegel W: Chemoradiotherapy
for colorectal cancer. Gut. 54:1194–1202. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carpenter G and Cohen S: Epidermal growth
factor. J Biol Chem. 265:7709–7712. 1990.PubMed/NCBI
|
|
6
|
Douillard JY, Siena S, Cassidy J,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Randomized, phase III trial of panitumumab with
infusional fluorouracil, leucovorin and oxaliplatin (FOLFOX4)
versus FOLFOX4 alone as first-line treatment in patients with
previously untreated metastatic colorectal cancer: The PRIME study.
J Clin Oncol. 28:4697–4705. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lacouture ME, Mitchell EP, Piperdi B,
Pillai MV, Shearer H, Iannotti N, Xu F and Yassine M: Skin toxicity
evaluation protocol with panitumumab (STEPP), a phase II,
open-label, randomized trial evaluating the impact of a pre-emptive
skin treatment regimen on skin toxicities and quality of life in
patients with metastatic colorectal cancer. J Clin Oncol.
28:1351–1357. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Peeters M, Price TJ, Cervantes A, Sobrero
AF, Ducreux M, Hotko Y, André T, Chan E, Lordick F, Punt CJ, et al:
Randomized phase III study of panitumumab with fluorouracil,
leucovorin and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal
cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
De Roock W, De Vriendt V, Normanno N,
Ciardiello F and Tejpar S: KRAS, BRAF, PIK3CA and PTEN mutations:
Implications for targeted therapies in metastatic colorectal
cancer. Lancet Oncol. 12:594–603. 2011. View Article : Google Scholar
|
|
10
|
Adjei AA: K-ras as a target for lung
cancer therapy. J Thorac Oncol. 3(6 Suppl 2): S160–S163. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Messersmith WA and Ahnen DJ: Targeting
EGFR in colorectal cancer. N Engl J Med. 359:1834–1836. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sadeghi S, Olevsky O and Hurvitz SA:
Profiling and targeting HER2-positive breast cancer using
trastuzumab emtansine. Pharmgenomics Pers Med. 7:329–338.
2014.PubMed/NCBI
|
|
13
|
Shak S: Overview of the trastuzumab
(Herceptin) anti-HER2 monoclonal antibody clinical program in
HER2-overexpressing metastatic breast cancer. Herceptin
multinational investigator study group. Semin Oncol. 26(4 Suppl
12): S71–S77. 1999.
|
|
14
|
Aurisicchio L, Marra E, Roscilli G,
Mancini R and Ciliberto G: The promise of anti-ErbB3 monoclonals as
new cancer therapeutics. Oncotarget. 3:744–758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mehta SP, Jose P, Mirza A, Pritchard SA,
Hayden JD and Grabsch HI: Comparison of the prognostic value of the
6th and 7th editions of the Union for International Cancer Control
TNM staging system in patients with lower esophageal cancer
undergoing neoadjuvant chemotherapy followed by surgery. Dis
Esophagus. 26:182–188. 2013. View Article : Google Scholar
|
|
16
|
Bustin SA, Benes V, Garson JA, Hellemans
J, Huggett J, Kubista M, Mueller R, Nolan T, Pfaffl MW, Shipley GL,
et al: The MIQE guidelines: Minimum information for publication of
quantitative real-time PCR experiments. Clin Chem. 55:611–622.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Caradec J, Sirab N, Keumeugni C, Moutereau
S, Chimingqi M, Matar C, Revaud D, Bah M, Manivet P, Conti M and
Loric S: 'Desperate house genes': The dramatic example of hypoxia.
Br J Cancer. 102:1037–1043. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schmittgen TD and Zakrajsek BA: Effect of
experimental treatment on housekeeping gene expression: Validation
by real-time, quantitative RT-PCR. J Biochem Biophys Methods.
46:69–81. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lupberger J, Kreuzer KA, Baskaynak G,
Peters UR, le Coutre P and Schmidt CA: Quantitative analysis of
beta-actin, beta-2-microglobulin and porphobilinogen deaminase mRNA
and their comparison as control transcripts for RT-PCR. Mol Cell
Probes. 16:25–30. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhong H and Simons JW: Direct comparison
of GAPDH, beta-actin, cyclophilin and 28S rRNA as internal
standards for quantifying RNA levels under hypoxia. Biochem Biophys
Res Commun. 259:523–526. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
de Kok JB, Roelofs RW, Giesendorf BA,
Pennings JL, Waas ET, Feuth T, Swinkels DW and Span PN:
Normalization of gene expression measurements in tumor tissues:
Comparison of 13 endogenous control genes. Lab Invest. 85:154–159.
2005. View Article : Google Scholar
|
|
22
|
Biederman J, Yee J and Cortes P:
Validation of internal control genes for gene expression analysis
in diabetic glomerulosclerosis. Kidney Int. 66:2308–2314. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yarom N and Jonker DJ: The role of the
epidermal growth factor receptor in the mechanism and treatment of
colorectal cancer. Discov Med. 11:95–105. 2011.PubMed/NCBI
|
|
24
|
Spano JP, Lagorce C, Atlan D, Milano G,
Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF,
et al: Impact of EGFR expression on colorectal cancer patient
prognosis and survival. Ann Oncol. 16:102–108. 2005. View Article : Google Scholar
|
|
25
|
Lédel F, Hallström M, Ragnhammar P,
Öhrling K and Edler D: HER3 expression in patients with primary
colorectal cancer and corresponding lymph node metastases related
to clinical outcome. Eur J Cancer. 50:656–662. 2014. View Article : Google Scholar
|
|
26
|
Koenders PG, Peters WH, Wobbes T, Beex LV,
Nagengast FM and Benraad TJ: Epidermal growth factor receptor
levels are lower in carcinomatous than in normal colorectal tissue.
Br J Cancer. 65:189–192. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lievre A, Bachet JB, Boige V, Cayre A, Le
Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al: KRAS
mutations as an independent prognostic factor in patients with
advanced colorectal cancer treated with cetuximab. J Clin Oncol.
26:374–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Andreyev J and Cunningham D: Markers,
markers everywhere. Prognosis in colorectal cancer-time for a new
approach. J Clin Oncol. 19:286–288. 2001.PubMed/NCBI
|
|
29
|
Brink M, de Goeij AF, Weijenberg MP,
Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm
RA and van den Brandt PA: K-ras oncogene mutations in sporadic
colorectal cancer in the Netherlands cohort study. Carcinogenesis.
24:703–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Taback B, Bilchik AJ, Saha S, Nakayama T,
Wiese DA, Turner RR, Kuo CT and Hoon DS: Peptide nucleic acid clamp
PCR: A novel K-ras mutation detection assay for colorectal cancer
microme-tastases in lymph nodes. Int J Cancer. 111:409–414. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yunxia Z, Jun C, Guanshan Z, Yachao L,
Xueke Z and Jin L: Mutations in epidermal growth factor receptor
and K-ras in Chinese patients with colorectal cancer. BMC Med
Genet. 11:342010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bazan V, Migliavacca M, Zanna I, Tubiolo
C, Grassi N, Latteri MA, La Farina M, Albanese I, Dardanoni G,
Salerno S, et al: Specific codon 13 K-ras mutations are predictive
of clinical outcome in colorectal cancer patients, whereas codon 12
K-ras mutations are associated with mucinous histotype. Ann Oncol.
13:1438–1446. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Tzahar E, Waterman H, Chen X, Levkowitz G,
Karunagaran D, Lavi S, Ratzkin BJ and Yarden Y: A hierarchical
network of interreceptor interactions determines signal
transduction by Neu differentiation factor/neuregulin and epidermal
growth factor. Mol Cell Biol. 16:5276–5287. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pinkas-Kramarski R, Soussan L, Waterman H,
Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela
M and Yarden Y: Diversification of Neu differentiation factor and
epidermal growth factor signaling by combinatorial receptor
interactions. Embo J. 15:2452–2467. 1996.PubMed/NCBI
|
|
35
|
Lee D, Yu M, Lee E, Kim H, Yang Y, Kim K,
Pannicia C, Kurie JM and Threadgill DW: Tumor-specific apoptosis
caused by deletion of the ERBB3 pseudo-kinase in mouse intestinal
epithelium. J Clin Invest. 119:2702–2713. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Cho HS, Mason K, Ramyar KX, Stanley AM,
Gabelli SB, Denney DW Jr and Leahy DJ: Structure of the
extracellular region of HER2 alone and in complex with the
herceptin fab. Nature. 421:756–760. 2003. View Article : Google Scholar : PubMed/NCBI
|
